Full Text:   <1323>

CLC number: R9

On-line Access: 

Received: 2005-02-02

Revision Accepted: 2005-03-03

Crosschecked: 0000-00-00

Cited: 13

Clicked: 4776

Citations:  Bibtex RefMan EndNote GB/T7714

-   Go to

Article info.
1. Reference List
Open peer comments

Journal of Zhejiang University SCIENCE B 2005 Vol.6 No.5 P.446~450

10.1631/jzus.2005.B0446


Pharmacokinetics of gemcitabine in Chinese patients with non-small-cell lung cancer


Author(s):  WANG Lin-run, HUANG Ming-zhu, XU Nong, SHENTU Jian-zhong, LIU Jian, CAI Jie

Affiliation(s):  First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China

Corresponding email(s):   linrunw@yahoo.com.cn

Key Words:  Gemcitabine, Non-small-cell lung cancer, Pharmacokinetics


Share this article to: More <<< Previous Article|

WANG Lin-run, HUANG Ming-zhu, XU Nong, SHENTU Jian-zhong, LIU Jian, CAI Jie. Pharmacokinetics of gemcitabine in Chinese patients with non-small-cell lung cancer[J]. Journal of Zhejiang University Science B, 2005, 6(5): 446~450.

@article{title="Pharmacokinetics of gemcitabine in Chinese patients with non-small-cell lung cancer",
author="WANG Lin-run, HUANG Ming-zhu, XU Nong, SHENTU Jian-zhong, LIU Jian, CAI Jie",
journal="Journal of Zhejiang University Science B",
volume="6",
number="5",
pages="446~450",
year="2005",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.2005.B0446"
}

%0 Journal Article
%T Pharmacokinetics of gemcitabine in Chinese patients with non-small-cell lung cancer
%A WANG Lin-run
%A HUANG Ming-zhu
%A XU Nong
%A SHENTU Jian-zhong
%A LIU Jian
%A CAI Jie
%J Journal of Zhejiang University SCIENCE B
%V 6
%N 5
%P 446~450
%@ 1673-1581
%D 2005
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.2005.B0446

TY - JOUR
T1 - Pharmacokinetics of gemcitabine in Chinese patients with non-small-cell lung cancer
A1 - WANG Lin-run
A1 - HUANG Ming-zhu
A1 - XU Nong
A1 - SHENTU Jian-zhong
A1 - LIU Jian
A1 - CAI Jie
J0 - Journal of Zhejiang University Science B
VL - 6
IS - 5
SP - 446
EP - 450
%@ 1673-1581
Y1 - 2005
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.2005.B0446


Abstract: 
To determine the pharmacokinetics of gemcitabine (2′,2′-difluorodeoxycytidine) in Chinese non-small-cell lung cancer (NSCLC) patients. Six study subjects were administered gemcitabine at a fixed dose rate of 10 mg/m2 per min (1200 mg/m2, two hours infusion), and carboplatin and plasma gemcitabine concentrations were measured by ion-pair reversed-phase high-performance liquid chromatography (HPLC). 3P97 Pharmaceutical Kinetics Software was used for the calculation of pharmacokinetic parameters. The obtained mean parameters, elimnation half life (t1/2) (10.67±3.38 min), area under the curve (AUC) (7.55±1.53 (µg·h)/ml), and clearance (CL) (3940.05±672.08 ml/min), were consistent with those reported in literature. The hematologic toxicology result showed that the regimen was effective on and tolerated by the patients.

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article

Reference

[1] Abbruzzese, J.L., Grunewald, R., Weeks, E.A., Gravel, D., Adams, T., Nowak, B., Mineishi, S., Tarassoff, P., 1991. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol, 9(3):491-498.

[2] Abratt, R.P., Bezwoda, W.R., Falkson, G., Goehals, L., Hacking, D., Rugg, T.A., 1994. Efficacy and safety profile of gemcitabine in non-small cell lung cancer: a phase II study. J Clin Oncol, 12(8):1535-1540.

[3] Anderson, H., Lund, B., Bach, F., Thatcher, N., Walling, J., Hansen, H.H., 1994. Single agent activity of weekly gemcitabine in advanced non-small cell lung cancer: a phase II study. J Clin Oncol, 12(9):1821-1826.

[4] Bhargava, P., Marshall, J.L., Fried, K., Williams, M., Lefebvre, P., Dahut, W., Hanfelt, J., Gehan, E., Figuera, M., Hawkins, M.J., Rizvi, N.A., 2001. Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancer. Cancer Chemother Pharmacol, 48(2):95-103.

[5] Gandhi, V., Plunkett, W., 1990. Modulatory activity of 2′,2′-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides. Cancer Res, 50(12):3675-3680.

[6] Green, M.R., 1996. Gemcitabine safety overview. Semin Oncol, 23(5 suppl 10):32-35.

[7] Grunewald, R., Kantarjian, H., Keating, M.J., Abbruzzese, J., Tarassoff, P., Plunkett, W., 1990. Pharmacologically directed design of the dose rate and schedule of 2′,2′-difluorodeoxycytidine (gemcitabine) administration in leukemia patients. Cancer Res, 50(21):6823-6826.

[8] Grunewald, R., Abbruzzese, J.L., Tarassoff, P., Plunkett, W., 1991. Saturation of 2′,2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol, 27(4):258-262.

[9] Guchelaar, H.J., Richel, D.J., van Knapen, A., 1996. Clinical, toxicological and pharmacological aspects of gemcitabine. Cancer Treat Rev, 22(1):15-31.

[10] Huang, P., Chubb, S., Hertel, L.W., Grindey, G.B., Plunkett, W., 1991. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res, 51(22):6110-6117.

[11] Kroep, J.R., Giaccone, G., Voorn, D.A., Smit, E.F., Beijnen, J.H., Rosing, H., van Moorsel, C.J., van Groeningen, C.J., Postmus, P.E., Pinedo, H.M., Peters, G.J., 1999. Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. J Clin Oncol, 17(7):2190-2197.

[12] Lund, B., Ryberg, M., Petersen, P.M., Anderson, H., Thatcher, N., Dombernowsky, P., 1994. Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) given as a twice weekly schedule to previously untreated patients with non-small cell lung cancer. Ann Oncol, 5(9):852-853.

[13] Manuel, D., Laura, G.E., Ana, L., 2002. A phase II trial of a two hour infusion of gemcitabine with carboplatin for advanced non-small-cell lung cancer (NSCLC). Ann Oncol, 13(suppl. 5):143.

[14] Ruiz van Haperen, V.W., Veerman, G., Vermorken, J.B., Peters, G.J., 1993. 2′,2′-difluorodeoxycytidine (gemcitabine) incorporation into RNA and DNA of tumor cell lines. Biochem Pharmacol, 46(4):762-766.

[15] Shord, S.S., Faucette, S.R., Gillenwater, H.H., Pascatore, S.L., Hawke, R.L., Socinski, M.A., Lindley, C., 2003. Gemcitabine pharmacokinetics and interaction with paclitaxel in patients with advanced non-small-cell lung cancer. Cancer Chemother pharmacol, 51(4):328-336.

[16] Storniolo, A.M., Allerheiligen, S.R., Pearce, H.L., 1997. Preclinical, pharmacologic, and phase I studies of gemcitabine. Semin Oncol, 24(2 Suppl 7):2-7.

[17] Tempero, M., Plunkett, W., Ruiz van Haperen, V., Hainsworth, J., Hochster, H., Lenzi, R., Abbruzzese, J., 2003. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol, 21(18):3402-3408.

Open peer comments: Debate/Discuss/Question/Opinion

<1>

Please provide your name, email address and a comment





Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou 310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn
Copyright © 2000 - Journal of Zhejiang University-SCIENCE